{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:38:21Z","timestamp":1740166701453,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T00:00:00Z","timestamp":1400025600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1038\/ja.2014.30","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T06:19:59Z","timestamp":1400048399000},"page":"505-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients"],"prefix":"10.1038","volume":"67","author":[{"given":"Kenneth VI","family":"Rolston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-0428","authenticated-orcid":false,"given":"Lior","family":"Nesher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Shelburne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall A","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,14]]},"reference":[{"issue":"Suppl 1","key":"BFja201430_CR1","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.ijantimicag.2007.06.012","volume":"30","author":"J Klastersky","year":"2007","unstructured":"Klastersky, J. et al. Bacteraemia in febrile neutropenic cancer patients. Int. J. Antimicrob. Agents. 30 (Suppl 1), S51\u2013S59 (2007).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"BFja201430_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10096-013-1819-7","volume":"32","author":"E Montassier","year":"2013","unstructured":"Montassier, E., Batard, E., Gastinne, T., Potel, G. & de La Cochetiere, M. F. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur. J. Clin. Microbiol. Infect. Dis. 32, 841\u2013850 (2013).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"BFja201430_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/JCM.44.1.160-165.2006","volume":"44","author":"XY Han","year":"2006","unstructured":"Han, X. Y., Kamana, M. & Rolston, K. V. Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J. Clin. Microbiol. 44, 160\u2013165 (2006).","journal-title":"J. Clin. Microbiol."},{"key":"BFja201430_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jinf.2012.11.007","volume":"66","author":"SA Shelburne 3rd","year":"2013","unstructured":"Shelburne, S. A. 3rd, Tarrand, J. & Rolston, K. V. Review of streptococcal bloodstream infections at a comprehensive cancer care center, 2000\u20132011. J. Infect. 66, 136\u2013146 (2013).","journal-title":"J. Infect."},{"issue":"Suppl 1","key":"BFja201430_CR5","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1086\/491708","volume":"42","author":"RC Moellering Jr.","year":"2006","unstructured":"Moellering, R. C. Jr. Vancomycin: a 50-year reassessment. Clin. Infect. Dis. 42 (Suppl 1), S3\u2013S4 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201430_CR6","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld, A. G. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 52, e56\u2013e93 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201430_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/jac\/dkm258","volume":"60","author":"G Steinkraus","year":"2007","unstructured":"Steinkraus, G., White, R. & Friedrich, L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60, 788\u2013794 (2007).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFja201430_CR8","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/cncr.21801","volume":"106","author":"A Safdar","year":"2006","unstructured":"Safdar, A. & Rolston, K. V. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer 106, 1815\u20131820 (2006).","journal-title":"Cancer"},{"key":"BFja201430_CR9","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1086\/605636","volume":"49","author":"SK Pillai","year":"2009","unstructured":"Pillai, S. K. et al. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin. Infect. Dis. 49, 1169\u20131174 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201430_CR10","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","volume":"42","author":"G Sakoulas","year":"2004","unstructured":"Sakoulas, G. et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42, 2398\u20132402 (2004).","journal-title":"J. Clin. Microbiol."},{"key":"BFja201430_CR11","unstructured":"CLSI.. Performance Standards for antimicrobial susceptibility testing. CLSI approved standard M100-S20, CLSI: Wayne, PA, USA, (2010)."},{"key":"BFja201430_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"SJ van Hal","year":"2012","unstructured":"van Hal, S. J., Lodise, T. P. & Paterson, D. L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54, 755\u2013771 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201430_CR13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijantimicag.2008.05.007","volume":"32","author":"DI Hsu","year":"2008","unstructured":"Hsu, D. I. et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents. 32, 378\u2013385 (2008).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"BFja201430_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu, C. et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52, 285\u2013292 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201430_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijantimicag.2012.10.016","volume":"41","author":"R Hope","year":"2013","unstructured":"Hope, R., Chaudhry, A., Adkin, R. & Livermore, D. M. In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci. Int. J. Antimicrob. Agents. 41, 213\u2013217 (2013).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"BFja201430_CR16","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1128\/AAC.00011-12","volume":"56","author":"RE Mendes","year":"2012","unstructured":"Mendes, R. E., Sader, H. S., Farrell, D. J. & Jones, R. N. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. Antimicrob. Agents. Chemother. 56, 3999\u20134004 (2012).","journal-title":"Antimicrob. Agents. Chemother."},{"key":"BFja201430_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ijantimicag.2013.01.014","volume":"41","author":"KV Rolston","year":"2013","unstructured":"Rolston, K. V., Kapadia, M., Tarrand, J., Coyle, E. & Prince, R. A. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients. Int. J. Antimicrob. Agents. 41, 516\u2013520 (2013).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"BFja201430_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1086\/339215","volume":"34","author":"WT Hughes","year":"2002","unstructured":"Hughes, W. T. et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34, 730\u2013751 (2002).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201430_CR19","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1086\/425009","volume":"39","author":"RW Finberg","year":"2004","unstructured":"Finberg, R. W. et al. The importance of bactericidal drugs: future directions in infectious disease. Clin. Infect. Dis. 39, 1314\u20131320 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201430_CR20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1634\/theoncologist.2012-0029","volume":"17","author":"SN Mahajan","year":"2012","unstructured":"Mahajan, S. N. et al. Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist 17, 1329\u20131336 (2012).","journal-title":"Oncologist"},{"key":"BFja201430_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jac\/dks354","volume":"68","author":"B Gu","year":"2013","unstructured":"Gu, B., Kelesidis, T., Tsiodras, S., Hindler, J. & Humphries, R. M. The emerging problem of linezolid-resistant Staphylococcus. J. Antimicrob. Chemother. 68, 4\u201311 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFja201430_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.diagmicrobio.2011.09.023","volume":"72","author":"RE Mendes","year":"2012","unstructured":"Mendes, R. E., Sader, H. S., Farrell, D. J. & Jones, R. N. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009). Diagn. Microbiol. Infect. Dis. 72, 113\u2013117 (2012).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"BFja201430_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2011.05.012","volume":"71","author":"RE Mendes","year":"2011","unstructured":"Mendes, R. E., Sader, H. S., Farrell, D. J. & Jones, R. N. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010). Diagn. Microbiol. Infect. Dis. 71, 93\u201397 (2011).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"BFja201430_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/SMJ.0b013e31821e91b1","volume":"104","author":"A Klotchko","year":"2011","unstructured":"Klotchko, A., Wallace, M. R., Licitra, C. & Sieger, B. Staphylococcus lugdunensis: an emerging pathogen. South. Med. J. 104, 509\u2013514 (2011).","journal-title":"South. Med. J."},{"key":"BFja201430_CR25","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s10096-013-1883-z","volume":"32","author":"K Smith","year":"2013","unstructured":"Smith, K., Gemmell, C. G. & Lang, S. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models. Eur. J. Clin. Microbiol. Infect. Dis. 32, 1327\u20131332 (2013).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"BFja201430_CR26","first-page":"61","volume":"13","author":"GA Pankey","year":"2013","unstructured":"Pankey, G. A. & Ashcraft, D. S. In Vitro Synergy of telavancin and rifampin against enterococcus faecium resistant to both linezolid and vancomycin. Ochsner J. 13, 61\u201365 (2013).","journal-title":"Ochsner J."},{"key":"BFja201430_CR27","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1086\/587896","volume":"46","author":"ME Stryjewski","year":"2008","unstructured":"Stryjewski, M. E. et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis. 46, 1683\u20131693 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201430_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/cid\/ciq031","volume":"52","author":"E Rubinstein","year":"2011","unstructured":"Rubinstein, E. et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin. Infect. Dis. 52, 31\u201340 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201430_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jac\/dkp001","volume":"63","author":"SS Hegde","year":"2009","unstructured":"Hegde, S. S., Difuntorum, S., Skinner, R., Trumbull, J. & Krause, K. M. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J. Antimicrob. Chemother. 63, 763\u2013766 (2009).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFja201430_CR30","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/jac\/dkl222","volume":"58","author":"N Reyes","year":"2006","unstructured":"Reyes, N. et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58, 462\u2013465 (2006).","journal-title":"J. Antimicrob. Chemother."}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ja201430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja201430","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja201430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:21:15Z","timestamp":1684430475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ja201430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,14]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["BFja201430"],"URL":"https:\/\/doi.org\/10.1038\/ja.2014.30","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"type":"print","value":"0021-8820"},{"type":"electronic","value":"1881-1469"}],"subject":[],"published":{"date-parts":[[2014,5,14]]},"assertion":[{"value":"18 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}